← Leaderboards
Patricia M Lorusso
Wayne State University
$29,646,459
Attributed
$30,138,323
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.4M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$30,138,323 · 5
By mechanism
UM1$20,169,612 · 1
U01$8,359,562 · 1
R21$1,357,789 · 2
UH2$251,360 · 1
Top collaborators
- Jordan D Berlin1 shared
- Kurt A Schalper1 shared
Most similar at Wayne State University
Same institution · by research overlap
- Larry H. Matherly$14,225,491
- Aleem Gangjee$13,765,845
- Asfar S Azmi$3,644,683
- Anthony Frank Shields$10,178,885
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorDesignMalignant NeoplasmsToxic EffectDrug KineticsPharmacodynamicsClinical TrialsUniversitiesTranslational ResearchAntineoplastic AgentsCancer CenterResearch PersonnelResponseInstitutionDrug DevelopmentPharmaceutical PreparationsSolid NeoplasmBaseInstitutesServicesResistanceDoseBiological MarkersBench To Bedside
Grant awards (37)
VICKtOrY Early Clinical Trials Consortium$1,249,062
UM1 · FY2025 · CA · contact PI
Multiplexed spatially resolved tissue biomarkers for optimal use of PD-1 axis blockers and PARP inhibitors in cancer.$251,360
UH2 · FY2025 · CA
VICKtOrY Early Clinical Trials Consortium$1
UM1 · FY2024 · CA · contact PI
VICKtOrY Early Clinical Trials Consortium$2,044,455
UM1 · FY2023 · CA · contact PI
Supplement to UM1 grant for NCI's Early Therapeutics Clinical Trials Network (ETCTN)$500,000
UM1 · FY2022 · CA · contact PI
VICKtOrY Early Clinical Trials Consortium$87,757
UM1 · FY2022 · CA · contact PI
Integration of single cell sequencing as a biomarker of PARP inhibitor response for IDH1 and IDH2 mutated AML and MDS$123,583
UM1 · FY2021 · CA · contact PI
Serial monitoring of circulating cell-free tumor DNA as measured by duplex sequencing in older patients with acute myeloid leukemia who receive azacitidine+venetoclax +/- immune checkpoint blockade$108,302
UM1 · FY2021 · CA · contact PI
Administrative Supplement for VICKtOrY Early Clinical Trials Consortium$100,000
UM1 · FY2021 · CA · contact PI
VICKtOrY Early Clinical Trials Consortium$7,379,439
UM1 · FY2020 · CA · contact PI
ViKTriY Early Clinical Trials Consortium (ECTC)$1,914,442
UM1 · FY2019 · CA · contact PI
Administrative Supplement to Support Preclinical Studies for Rogaratinib (NSC #804782) Clinical Trials$119,227
UM1 · FY2019 · CA · contact PI
ViKTriY Early Clinical Trials Consortium (ECTC)$1,325,865
UM1 · FY2018 · CA · contact PI
ViKTriY Early Clinical Trials Consortium (ECTC)$1,362,459
UM1 · FY2016 · CA · contact PI
ViKTriY-PC Consortium Phase II Supplement$732,368
UM1 · FY2016 · CA · contact PI
ViKTriY Early Clinical Trials Consortium (ECTC)$167,500
UM1 · FY2016 · CA · contact PI
ViKTriY Early Clinical Trials Consortium (ECTC)$1,535,152
UM1 · FY2015 · CA · contact PI
ViKTriY Early Clinical Trials Consortium (ECTC)$1,420,000
UM1 · FY2014 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents$620,359
U01 · FY2013 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents$601,787
U01 · FY2012 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents$605,617
U01 · FY2011 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents$628,089
U01 · FY2010 · CA · contact PI
Correlative Studies for NCI Study#7916: Phase I Clinical Trial of Intravenous FAU$334,400
R21 · FY2010 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents$853,019
U01 · FY2009 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents$618,333
U01 · FY2009 · CA · contact PI
Correlative Studies for NCI Study #7977: Phase I trial of ABT-888 Plus Irinotecan$338,176
R21 · FY2009 · CA · contact PI
Correlative Studies for NCI Study#7916: Phase I Clinical Trial of Intravenous FAU$334,400
R21 · FY2009 · CA · contact PI
Early Clinical Trials of New Anti-Cancer Agents$613,306
U01 · FY2008 · CA · contact PI
Correlative Studies for NCI Study #7977: Phase I trial of ABT-888 Plus Irinotecan$350,813
R21 · FY2008 · CA · contact PI
Phase I Clinical Trials of New Anticancer Agents$542,384
U01 · FY2007 · CA · contact PI
Phase I Clinical Trials of New Anticancer Agents$543,337
U01 · FY2006 · CA · contact PI
Phase I Clinical Trials of New Anticancer Agents$445,636
U01 · FY2005 · CA
Phase I Clinical Trials of New Anticancer Agents$524,960
U01 · FY2004 · CA
Phase I Clinical Trials of New Anticancer Agents$516,952
U01 · FY2003 · CA
PHASE I TRIALS OF ANTICANCER AGENTS$459,076
U01 · FY2002 · CA
PHASE I TRIALS OF ANTICANCER AGENTS$419,639
U01 · FY2001 · CA
PHASE I TRIALS OF ANTICANCER AGENTS$367,068
U01 · FY2000 · CA